Safety profiles of old and new antimicrobials for the treatment of MRSA infections

Expert Opinion on Drug Safety
Matteo Bassetti, Elda Righi

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is a frequent cause of severe nosocomial and community-acquired infections. Various adverse effects have been associated with compounds that are commonly used in the treatment of MRSA. Prolonged use of high-dose vancomycin has been linked with nephrotoxicity. Linezolid use has been associated with lactic acidosis in regimens longer than 14 days and occurrence of thrombocytopenia in patients with renal impairment. Daptomycin use correlates with reversible and often asymptomatic myopathy. Among new compounds, telavancin has shown increased toxicity compared to vancomycin, especially in patients with severe renal impairment, while a low rate of adverse effects was reported others glycolipopeptides such as dalbavancin and oritavancin and for new cephalosporins. Recently studied oxazolidinones (tedizolid and radezolid) also showed mild adverse effects in Phase 2 and 3 clinical trials. Due to the constant increase in antimicrobial resistance, the use of higher doses and prolonged regimens of antibiotics employed in the treatment of Gram-positive infections has become more common and linked to increased toxicity. Furthermore, new compounds with MRSA activity have been recently approve...Continue Reading

References

Dec 11, 1991·Antimicrobial Agents and Chemotherapy·N E AllenJ N Hobbs
Aug 23, 1991·Pharmaceutisch Weekblad. Scientific Edition·R Janknegt
May 1, 1997·Trends in Microbiology·C W FordG E Zurenko
Aug 26, 1998·International Journal of Antimicrobial Agents·A P Wilson
Oct 6, 2000·The Journal of Antimicrobial Chemotherapy·F P Tally, M F DeBruin
Oct 19, 2000·Antimicrobial Agents and Chemotherapy·F B OlesonF P Tally
Dec 12, 2001·Psychosomatics·S LaveryY R Pushkin
Dec 18, 2001·Biopharmaceutics & Drug Disposition·I R WelshmanN K Hopkins
Jan 23, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kinan AttassiMarcus J Zervos
Jul 18, 2002·Antimicrobial Agents and Chemotherapy·Stanton L GersonDavid J Kuter
Dec 20, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sara E CosgroveYehuda Carmeli
Jan 3, 2003·The New England Journal of Medicine·Aaron A Apodaca, Robert M Rakita
Jan 11, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mary C BirminghamJerome J Schentag
Apr 19, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P F SmithJ J Schentag
May 2, 2003·Critical Care : the Official Journal of the Critical Care Forum·Soupramanien Sivagnanam, Dirk Deleu
May 23, 2003·Antimicrobial Agents and Chemotherapy·Ethan RubinsteinJack Remington
May 23, 2003·Antimicrobial Agents and Chemotherapy·Ellie J C GoldsteinHelen T Fernandez
Aug 26, 2003·Antimicrobial Agents and Chemotherapy·Michael E BrierGail L Jungbluth
Feb 27, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·L LegoutY Mouton
Mar 5, 2004·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Salih Cesur, Fügen Cokça
Mar 12, 2004·International Journal of Antimicrobial Agents·Bülent Bozdogan, Peter C Appelbaum
Jul 1, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert D ArbeitUNKNOWN Daptomycin 98-01 and 99-01 Investigators
Aug 27, 2004·The Journal of Antimicrobial Chemotherapy·Eric SennevilleYves Mouton
Dec 24, 2004·Antimicrobial Agents and Chemotherapy·J P ShawS Barriere
May 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Martin E StryjewskiUNKNOWN FAST Investigator Group
Jul 5, 2005·Expert Opinion on Investigational Drugs·F P TallyF B Oleson
Jul 21, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J Todd Weber
Oct 19, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Luis E JaureguiWilliam O'Riordan
Nov 25, 2005·The New England Journal of Medicine·Alex SorianoJosep Mensa
Dec 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Donald P Levine
Feb 24, 2006·Antimicrobial Agents and Chemotherapy·Martin E StryjewskiUNKNOWN FAST 2 Investigator Group
Jun 17, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jeremy J TaylorLynn L Estes
Aug 18, 2006·The New England Journal of Medicine·Vance G FowlerUNKNOWN S. aureus Endocarditis and Bacteremia Study Group
Aug 29, 2006·International Journal of Antimicrobial Agents·Yen-Hung LinPo-Ren Hsueh
Feb 28, 2007·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Simone ShurlandMary-Claire Roghmann
Jun 27, 2007·Antimicrobial Agents and Chemotherapy·Anne Marie QueenanKaren Bush
Oct 9, 2007·The American Journal of Emergency Medicine·Alain ViallonJean Claude Bertrand
Oct 18, 2007·Pharmacology·Robert SauermannChristian Joukhadar
Jan 4, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alex SorianoJosep Mensa
Jan 30, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Gary J NoelRichard S Strauss
Feb 7, 2008·Expert Review of Anti-infective Therapy·George G ZhanelJames A Karlowsky
Mar 5, 2008·Antimicrobial Agents and Chemotherapy·Laura LawrenceJoyce Sutcliffe
Mar 15, 2008·The Journal of Antimicrobial Chemotherapy·Dilip NathwaniUNKNOWN British Society for Antimicrobial Chemotherapy Working Party on Community-onset MRSA Infections

❮ Previous
Next ❯

Citations

Apr 28, 2016·Expert Review of Vaccines·Gustavo H DayanAnnaliesa S Anderson
Aug 27, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S Esposito, S Bianchini
Jan 31, 2017·Current Opinion in Infectious Diseases·Garyphallia PoulakouSotirios Tsiodras
Oct 12, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Richard R Watkins, Stan Deresinski
Jan 22, 2019·Current Opinion in Infectious Diseases·Elda RighiMatteo Bassetti
Feb 21, 2019·Expert Opinion on Pharmacotherapy·Daniele Roberto GiacobbeClaudio Viscoli
May 21, 2019·Expert Opinion on Drug Safety·Matteo BassettiDaniele Roberto Giacobbe
Mar 16, 2016·Annals of Clinical Microbiology and Antimicrobials·R Andrew SeatonKamal Hamed
Jul 14, 2018·Infectious Diseases and Therapy·Sergey ShlyapnikovMark H Wilcox
Oct 28, 2019·Antimicrobial Resistance and Infection Control·Tobias Siegfried KramerSeven Johannes Sam Aghdassi
Jan 22, 2021·Bioorganic & Medicinal Chemistry Letters·Qidi Kong, Yushe Yang
Apr 3, 2021·Journal of Molecular Graphics & Modelling·G I Makarov, R V Reshetnikova
Jul 15, 2021·Expert Opinion on Drug Safety·Gianpaolo PerlettiVittorio Magri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Keith A Rodvold, Kevin W McConeghy
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Scott T Micek
Seminars in Respiratory and Critical Care Medicine
Elizabeth A NeunerScott T Micek
Nefrología : publicación oficial de la Sociedad Española Nefrologia
M Montejo
© 2022 Meta ULC. All rights reserved